Stryker reported net sales of 1.995 billion for the fourth quarter of 2010, an 8.8 percent increase over the net sales of the fourth quarter of 2009, according to a company news release.
The company can attribute its success to several strategic acquisitions that enhanced the core products offered by the company. The sale of the OP-1 product family allowed the company to refocus biologic research and development activities.
Stryker repurchased 6.1 million shares at a cost of $314 million during the fourth quarter. Domestic sales were reported as $1.286 billion during the fourth quarter, an 11 percent increase from last year. The international sales were $710 million, a 5 percent increase from last year.
Worldwide orthopedic implant sales were reported as $1.166 billion during the fourth quarter, a 4.5 percent increase from last year.
Read the Stryker release on the 4Q FY 2010 financial report.
Read other coverage on Stryker:
- Stryker Expands Its Board of Directors
- Stryker Sells OP-1 Products to Olympus Corp. for $60M
- Stryker Purchases Porex Surgical
The company can attribute its success to several strategic acquisitions that enhanced the core products offered by the company. The sale of the OP-1 product family allowed the company to refocus biologic research and development activities.
Stryker repurchased 6.1 million shares at a cost of $314 million during the fourth quarter. Domestic sales were reported as $1.286 billion during the fourth quarter, an 11 percent increase from last year. The international sales were $710 million, a 5 percent increase from last year.
Worldwide orthopedic implant sales were reported as $1.166 billion during the fourth quarter, a 4.5 percent increase from last year.
Read the Stryker release on the 4Q FY 2010 financial report.
Read other coverage on Stryker:
- Stryker Expands Its Board of Directors
- Stryker Sells OP-1 Products to Olympus Corp. for $60M
- Stryker Purchases Porex Surgical